<SEC-DOCUMENT>0001144204-11-028557.txt : 20110512
<SEC-HEADER>0001144204-11-028557.hdr.sgml : 20110512
<ACCEPTANCE-DATETIME>20110512160525
ACCESSION NUMBER:		0001144204-11-028557
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20110512
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110512
DATE AS OF CHANGE:		20110512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TRANSGENOMIC INC
		CENTRAL INDEX KEY:			0001043961
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				911789357
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30975
		FILM NUMBER:		11835857

	BUSINESS ADDRESS:	
		STREET 1:		12325 EMMET ST
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
		BUSINESS PHONE:		4027385480

	MAIL ADDRESS:	
		STREET 1:		12325 EMMET STREET
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v222286_8k.htm
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNITED STATES</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington, D.C.&#160;&#160;20549</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FORM 8-K</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CURRENT REPORT</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to Section&#160;13 OR 15(d) of The Securities Exchange Act of 1934</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date of Report (Date of earliest event reported):</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">May 12, 2011</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">TRANSGENOMIC, INC.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact name of registrant as specified in its charter)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div>&#160;</div>

<div>
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr>
<td valign="top" width="15%" style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Delaware</font></div>
</td>
<td align="left" valign="top" width="5%" style="PADDING-BOTTOM: 1px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td valign="top" width="15%" style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">000-30975</font></div>
</td>
<td align="left" valign="top" width="5%" style="PADDING-BOTTOM: 1px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td valign="top" width="15%" style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">911789357</font></div>
</td>
</tr><tr>
<td valign="top" width="15%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(State of Incorporation)&#160;</font></td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="15%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;(Commission File Number)</font></td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="15%" style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(IRS Employer Identification </font></div>

<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Number)</font></font></div>
</td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br>
<div>&#160;</div>

<div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; ">
<tr>
<td valign="top" width="10%" style="PADDING-BOTTOM: 1px; TEXT-ALIGN: center">&#160;</td>
<td valign="top" width="39%" style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">12325 Emmet Street, Omaha, Nebraska</td>
<td align="left" valign="top" width="24%" style="PADDING-BOTTOM: 1px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td valign="top" width="15%" style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">68164</font></div>
</td>
<td align="left" valign="top" width="10%" style="PADDING-BOTTOM: 1px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
</tr><tr>
<td valign="top" width="10%" style="TEXT-ALIGN: center">&#160;</td>
<td valign="top" width="39%" style="TEXT-ALIGN: center">(Address of principal executive offices)&#160;</td>
<td align="left" valign="top" width="24%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="15%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;(Zip Code)</font></td>
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div>&#160;</div>
</div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(402) 452-5400&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Registrant&#8217;s telephone number, including area code)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Not applicable&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Former name or former address, if changed since last report)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: ; ">
<tr valign="top">
<td align="right" style="WIDTH: 27pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: ; ">
<tr valign="top">
<td align="right" style="WIDTH: 27pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&#160;CFR 240.14d-2(b))</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&#160;CFR 240.13e-4(c))</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div>&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item 2.02 Results of Operations and Financial Condition</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On May 12, 2011, Transgenomic, Inc. issued a press release announcing its financial results for the first quarter 2011.&#160;&#160;A copy of the press release is being furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The information referenced in this Current Report on Form 8-K (including Exhibit 99 referenced in Item&#160;9.01 below) is being &#8216;furnished&#8221; under &#8220;Item 2.02. Results of Operations and Financial Condition&#8221; and, as such, shall not be deemed to be &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section.&#160;&#160;The information set forth in this Current Report on Form 8-K (including Exhibit 99 referenced in Item 9.01 below) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended (the&#160;&#8220;Securities Act&#8221;), except as shall be expressly set forth by specific reference in such filing.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item 9.01.&#160;&#160;Financial Statements and Exhibits.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(99)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Press release dated May 12, 2011, announcing Transgenomic, Inc.&#8217;s financial results for the first quarter 2011.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="">
<tr>
<td align="left" valign="top" width="39%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dated:&#160;&#160;May 12, 2011</font></div>
</td>
<td align="left" valign="top" width="41%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">TRANSGENOMIC, INC.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:&#160;&#160;&#160;&#160; <font style="DISPLAY: inline"><font style="TEXT-DECORATION: underline">/s/ Brett L. Frevert</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;&#160;Brett L. Frevert</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;&#160;Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v222286_ex99-1.htm
<TEXT>
<html><head><META content="text/html; charset=utf-8"></META></head><body style="font-size:10pt;font-family:Arial;color:black;"><div style="width:100%;margin-left:10pt"><p style="text-align:center"><b>Transgenomic Reports First Quarter Financial Results</b></p><br /><br /><p style="text-align:center">Net Sales of $7.5 million, up 37 percent Conference call begins at 5:00 p.m. Eastern Time today</p></div><div style="width:100%;margin-left:10pt;"><div style="margin:0;margin-top:16pt;"><p>OMAHA, Neb., May 12, 2011 /PRNewswire/ -- Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for the three months ended March 31, 2011, and provided a business update.</p><p>First Quarter Financial Results</p><p>Net sales for the first quarter of 2011 were $7.5 million, an increase of 37 percent compared with $5.4 million for the same period in 2010. Gross profit was $4.2 million or 56
percent of net sales, compared with gross profit of $2.9 million or 53 percent of net sales for the same period in 2010.  </p><p>The increase in revenue is primarily due to our recent acquisition of the FAMILION family of genetic tests on December 29, 2010, as we operated this business the entire quarter.  </p><p>Operating expenses were $4.9 million during the first quarter of 2011, compared with $3.3 million in the prior year. This increase in operating expenses is directly related to our FAMILION lab, including noncash charges totaling $300,000 relating to the amortization of the acquired intangibles.  </p><p>The net loss for the first quarter of 2011 was $2.8 million or $0.06 per share compared with a net loss of $324,000 or $0.01 per share for the first quarter of 2010. This was due primarily to the noncash Preferred Stock expenses, totaling $2.0 million, and the amortization of the
acquired intangible assets, which totaled $300,000.  Absent these expenses, our net loss would have been $460,000 for the first quarter of 2011.</p><p>Modified EBITDA improved to ($16,000) in the first quarter of 2011 from ($209,000) in the first quarter of 2010.</p><p>Cash and cash equivalents were $3.2 million as of March 31, 2011, compared with $3.5 million as of December 31, 2010.</p><p><u><b>Comment and Outlook</b></u></p><p>&#34;We are quite pleased with the quarter&#39;s results in both top-line growth and EBITDA improvement,&#34; commented Craig Tuttle, President and Chief Executive Officer for the company. &#34;When we completed our acquisition of the FAMILION business, we were challenged as a new corporate team to bring together two businesses that were losing a combined $7.5 million a year just prior to completing the acquisition. Our goals were to improve operating margins
immediately, complete the integration of our two CLIA-certified reference labs into a single lab operation and demonstrate significant improvement quickly.  In our first combined quarter, we are on track to meet all of these expectations.  In the second quarter, we will complete the final components of integrating our laboratories.  We also expect improvement in our Neurology testing business by expanding coverage under the managed care contracts which we secured with the Familion transaction. We are also very pleased with our customer retention efforts through the lab integration activities. All of our customer relationship efforts have proven effective.  Despite a soft start to the year in lab tests ordered during the Christmas holiday season, we have seen test request volume return to its previous level during the quarter.&#34;</p><p>&#34;We are also excited to see the increase in
testing volume in our Pharmacogenomics Services business,&#34; Tuttle further commented. &#34;We have increased the total number of projects being performed, increased our project pipeline and our total number of new contracted projects. This will continue to fuel growth in our Pharma services business both due to our expertise in mutation profiling for cancer drug trials and data for FDA submission as well as for new projects employing our Ice COLD-PCR and recently discovered BLOCker-Sequencing technologies.&#34;</p><p>Transgenomic anticipates growth in both our diagnostics and our laboratory services businesses as we commercialize new assay technologies and tests we have developed internally or in-licensed to expand our menu. In particular, we have substantially increased our footprint in the molecular diagnostics laboratory market through our acquisition of the FAMILION laboratory
testing business.  This acquisition brings us historic annual revenues of approximately $13.0 million and a much larger presence both with insurers and patients. This acquisition also provides us access to higher throughput technologies and an expert staff to aid us as we continue growing our reference laboratory business as well as consolidation opportunities already achieved in laboratory operations, billing and customer service functions. </p><p>In our Pharmacogenomic Services Lab, we continue to perform cancer pathway gene mutation analysis for a number of high visibility pharmaceutical companies both for pre-clinical drug discovery projects and phase II and III clinical trials.  Employing our recently licensed ultra sensitive DNA mutation detection technology, termed COLD-PCR, and a significant improvement to COLD-PCR termed Ice COLD-PCR; we can now analyze blood serum for DNA
mutations rather than just testing patients&#39; tumors. This is a significant achievement and should, we believe, lead to much faster expansion of our service testing for pharmaceutical partners as they adopt this novel approach for both drug and disease research. </p><p>In addition to Ice COLD-PCR, which offers sensitivity improvements as much as 1,000 times higher than routine DNA testing technology, we have recently discovered a technique to further improve mutation detection sensitivity of standard Sanger sequencing. We have termed this new discovery BLOCker-Sequencing and we are combining this new discovery with our Ice COLD-PCR program to bring what we believe to be the most accurate and sensitive mutation detection technology available in the market today. We believe that this combination of technologies offers us the ability to develop tests for cancer detection or to measure
cancer recurrence at earlier stages in the disease process aiding in drug selection or drug resistance determinations for these patients.  By giving physicians the tools to select or change therapy earlier in the disease process, we can help improve outcomes for cancer patients.  </p><p>We continue to leverage our core instrument business for on-going instrument and consumable supplies sales worldwide as well as employing our instrument technology and related expertise in our two laboratory services businesses. </p><p>Although the WAVE System is a fully matured technology, and both it and its corresponding consumable sales growth in our traditional markets are shrinking, we are expanding our opportunities by selling systems into new geographic areas, including the Middle East and Asia, to continue the revenue from our instrument related business segment.  We also continue to sell OEM
instruments worldwide for pre-analytical karyotyping automation and to select markets in Europe for Image Analysis. </p><p>During the first quarter, we launched a CE IVD labeled SURVEYOR Scan K-RAS mutation detection kit in Europe and have released two SURVEYOR Scan Research Use Only (RUO) kits for detecting mutations in key cancer pathway genes BRAF and PIK3CA.  Combining these key cancer pathway mutation assessment tools with our proprietary technologies brings noteworthy improvements in sensitivity and cost effectiveness to the market compared to competing technologies. </p><p>Finally, we continue to look for opportunities to diversify into new markets, particularly in oncology, where the sensitivities of our technologies provide significant clinical benefit. We have also embarked on several academic collaborations to further validate our newest technologies and better determine how
they can and will be used in clinical settings for patients undergoing treatment for cancer.</p><p><u><b>Conference Call</b></u></p><p>Transgenomic management will host a conference call to discuss first quarter 2011 financial results and answer questions beginning at 5:00 p.m. Eastern time today. To access the call via telephone, please dial 800-895-0198 from the U.S. and Canada or 785-424-1053 for international participants and enter the conference ID TRANS. The call also will be broadcast live over the Internet. To listen to the webcast, please log onto the Company&#39;s Investor Relations web page at http://www.transgenomic.com/events.asp?id=6 and follow the instructions. An archived webcast of the call will be available for 30 days. Investors can listen to a replay via telephone until 11:59 p.m. Eastern time on Thursday, May 26, 2011 by dialing 800-374-0328 (domestic) or
402-220-0663 (international).</p><p><u><b>About Transgenomic, Inc.</b></u></p><p>Transgenomic, Inc. (www.transgenomic.com) is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomic analyses.  Transgenomic, Inc. is comprised of 3 different divisions.  Transgenomic Molecular Lab specializes in molecular diagnostics for cardiology, neurology, mitochondrial disorders, oncology, hematology, molecular pathology and other inherited diseases.  Transgenomic Pharmacogenomic Services is a contract research service offering translational research and clinical trial services to pharmaceutical companies in support of pre-clinical and phase I, II and III clinical trials.  Transgenomic&#39;s Diagnostic Tools
Business product offerings include systems for the automation of sample processing and analysis for Cytogenetic and Molecular Diagnostic testing.  Transgenomic&#39;s WAVE<sup>&#174; </sup>Systems and associated consumables are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification.  SURVEYOR<sup>&#174; </sup>Scan Mutation Detection kits provide reagents and protocols for high sensitivity detection of mutations in key cancer pathway genes. HANABI automated chromosome harvesting systems improve laboratory productivity with consistent quality compared with manual methods for cytogenetic karyotyping and FISH analyses.  Transgenomic believes there is a significant opportunity to continue growing the demand for its molecular-based testing across all business lines by leveraging core technologies, experience and expertise in
biomarker analysis. In addition, the company continues to seek out and evaluate new technologies and new intellectual property to extend its offerings in molecular diagnostics and pharmacogenomic services.</p><p><u><b>Forward-Looking Statements</b></u></p><p>Certain statements in this press release constitute &#34;forward-looking statements&#34; of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management&#39;s current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including
the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic&#39;s filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by
law.</p><div style="margin-bottom:.0001in; margin-top:.0001in"><table cellspacing="0" cellpadding="1" style="border-collapse:collapse;border:none;"><tr><td valign="bottom" colspan="3" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; text-align: center; "><b><font style="font-family:Arial;font-size:8pt;">Transgenomic, Inc.</font></b></p><p style="margin:0in; text-align: center; "><b><font style="font-family:Arial;font-size:8pt;">Summary Financial Results</font></b></p><p style="margin:0in; text-align: center; "><b><font style="font-family:Arial;font-size:8pt;">Unaudited Condensed Consolidated Statements of Operations</font></b></p><p style="margin:0in; text-align: center; "><b><font style="font-family:Arial;font-size:8pt;">(dollars in thousands except per share data)</font></b></p><br /></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt
5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 14pt; padding-left: 10pt; "><br /></td><td valign="bottom" colspan="2" style="padding: 0pt 5.4pt 2pt 5.4pt;border-bottom:solid black 1pt; padding-right: 14pt; padding-left: 10pt; "><p style="margin:0in; text-align: center; "><b><font style="font-family:Arial;font-size:8pt;">Three Months Ended</font></b></p><p style="margin:0in; text-align: center; "><b><font style="font-family:Arial;font-size:8pt;">March 31,</font></b></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 14pt; padding-left: 10pt; "><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-top:solid black
1pt; border-bottom:solid black 1pt; padding-right: 14pt; padding-left: 10pt; "><p style="margin:0in; text-align: center; "><b><font style="font-family:Arial;font-size:8pt;">2011</font></b><font style="font-family:Arial;font-size:8pt;"></font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-top:solid black 1pt; border-bottom:solid black 1pt; padding-right: 14pt; padding-left: 10pt; "><p style="margin:0in; text-align: center; "><b><font style="font-family:Arial;font-size:8pt;">2010</font></b><font style="font-family:Arial;font-size:8pt;"></font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style=" margin:0in;"><b><font style="font-family:Arial;font-size:8pt;">NET SALES</font></b><font style="font-family:Arial;font-size:8pt;"></font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-top:solid
black 1pt; padding-right: 10pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">$ &#160;7,480</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-top:solid black 1pt; padding-right: 10pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">$ &#160;5,442</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style=" margin:0in;"><b><font style="font-family:Arial;font-size:8pt;">COST OF GOODS SOLD</font></b><font style="font-family:Arial;font-size:8pt;"></font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-bottom:solid black 1pt; padding-right: 10pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align:
right; "><font style="font-family:Arial;font-size:8pt;">3,326</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-bottom:solid black 1pt; padding-right: 10pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">2,558</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; margin-left: 24pt;"><font style="font-family:Arial;font-size:8pt;">Gross profit </font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-top:solid black 1pt; padding-right: 10pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">4,154</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-top:solid black 1pt;
padding-right: 10pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">2,884</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style=" margin:0in;"><b><font style="font-family:Arial;font-size:8pt;">OPERATING EXPENSES:</font></b></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 14pt; padding-left: 10pt; "><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 14pt; padding-left: 10pt; "><br /></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; margin-left: 24pt;"><font style="font-family:Arial;font-size:8pt;">Selling, general and administrative </font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 10pt;
padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">4,323</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 10pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">2,432</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; margin-left: 24pt;"><font style="font-family:Arial;font-size:8pt;">Research and development </font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 10pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">557</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt
5.4pt;padding-right: 10pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">827</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; margin-left: 24pt;"><font style="font-family:Arial;font-size:8pt;">Restructuring Charges</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-bottom:solid black 1pt; padding-right: 10pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">24</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-bottom:solid black 1pt; padding-right: 10pt; padding-left: 10pt; "><p style="margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">&#8212;</font></p></td><td
style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 14pt; padding-left: 10pt; "><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-top:solid black 1pt; border-bottom:solid black 1pt; padding-right: 10pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">4,904</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-top:solid black 1pt; border-bottom:solid black 1pt; padding-right: 10pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">3,259</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style=" margin:0in;"><b><font style="font-family:Arial;font-size:8pt;">LOSS FROM
OPERATIONS</font></b><font style="font-family:Arial;font-size:8pt;"></font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-top:solid black 1pt; padding-right: 6pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">(750)</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-top:solid black 1pt; padding-right: 6pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">(375)</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style=" margin:0in;"><b><font style="font-family:Arial;font-size:8pt;">OTHER INCOME (EXPENSE):</font></b></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 14pt; padding-left:
10pt; "><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 14pt; padding-left: 10pt; "><br /></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; margin-left: 24pt;"><font style="font-family:Arial;font-size:8pt;">Interest expense</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">(238)</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 10pt; padding-left: 10pt; "><p style="margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">&#8212;</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; margin-left:
24pt;"><font style="font-family:Arial;font-size:8pt;">Expense on preferred stock</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">(2,027)</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 10pt; padding-left: 10pt; "><p style="margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">&#8212;</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; margin-left: 24pt;"><font style="font-family:Arial;font-size:8pt;">Other, net </font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-bottom:solid black 1pt; padding-right: 10pt; padding-left: 10pt; "><p style="white-space:
nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">231</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-bottom:solid black 1pt; padding-right: 10pt; padding-left: 10pt; "><p style="margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">&#8212;</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-top:solid black 1pt; border-bottom:solid black 1pt; padding-right: 6pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">(2,034)</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-top:solid black 1pt; border-bottom:solid black 1pt; padding-right: 10pt; padding-left: 10pt; "><p
style="margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">&#8212;</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-top:solid black 1pt; padding-right: 14pt; padding-left: 10pt; "><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-top:solid black 1pt; padding-right: 14pt; padding-left: 10pt; "><br /></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style=" margin:0in;"><b><font style="font-family:Arial;font-size:8pt;">LOSS BEFORE INCOME TAXES </font></b></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font
style="font-family:Arial;font-size:8pt;">(2,784)</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">(375)</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style=" margin:0in;"><b><font style="font-family:Arial;font-size:8pt;">INCOME TAX BENEFIT</font></b></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-bottom:solid black 1pt; padding-right: 6pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">(6)</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-bottom:solid black 1pt; padding-right: 6pt; padding-left: 10pt; "><p
style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">(51)</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style=" margin:0in;"><b><font style="font-family:Arial;font-size:8pt;">NET LOSS </font></b></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-top:solid black 1pt; border-bottom:double black 2.5pt; padding-right: 6pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">$ &#160;(2,778)</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-top:solid black 1pt; border-bottom:double black 2.5pt; padding-right: 6pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">$
&#160;(324)</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-top:double black 2.5pt; padding-right: 14pt; padding-left: 10pt; "><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-top:double black 2.5pt; padding-right: 14pt; padding-left: 10pt; "><br /></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style=" margin:0in;"><b><font style="font-family:Arial;font-size:8pt;">Preferred stock dividends</font></b></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-bottom:solid black 1pt; padding-right: 6pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">(260)</font></p></td><td valign="bottom"
style="padding: 0pt 5.4pt 2pt 5.4pt;border-bottom:solid black 1pt; padding-right: 10pt; padding-left: 10pt; "><p style="margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">&#8212;</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style=" margin:0in;"><b><font style="font-family:Arial;font-size:8pt;">Net loss available to common stockholders</font></b></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-top:solid black 1pt; border-bottom:double black 2.5pt; padding-right: 6pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">$ &#160;(3,038)</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-top:solid black 1pt; border-bottom:double black 2.5pt; padding-right: 6pt; padding-left:
10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">$ &#160;(324)</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-top:double black 2.5pt; padding-right: 14pt; padding-left: 10pt; "><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-top:double black 2.5pt; padding-right: 14pt; padding-left: 10pt; "><br /></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style=" margin:0in;"><b><font style="font-family:Arial;font-size:8pt;">BASIC AND DILUTED LOSS PER COMMON SHARE</font></b></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-bottom:double black 2.5pt; padding-right: 6pt; padding-left: 10pt; "><p style="white-space:
nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">$ &#160;(0.06)</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-bottom:double black 2.5pt; padding-right: 6pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">$ &#160;(0.01)</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style=" margin:0in;"><b><font style="font-family:Arial;font-size:8pt;">BASIC AND DILUTED WEIGHTED AVERAGE SHARES OF COMMON STOCK OUTSTANDING </font></b></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-top:double black 2.5pt; border-bottom:double black 2.5pt; padding-right: 10pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font
style="font-family:Arial;font-size:8pt;">49,293,005</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;border-top:double black 2.5pt; border-bottom:double black 2.5pt; padding-right: 10pt; padding-left: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">49,189,672</font></p></td><td style=""></td></tr><tr><td valign="bottom" colspan="3" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td style=""></td></tr><tr><td style="padding: 0pt 5.4pt 2pt 5.4pt;"></td><td style="padding: 0pt 5.4pt 2pt 5.4pt;"></td><td style="padding: 0pt 5.4pt 2pt 5.4pt;"></td></tr></table><br /><br /></div><div style="margin-bottom:.0001in; margin-top:.0001in"><table cellspacing="0" cellpadding="1" style="border-collapse:collapse;border:none;"><tr><td valign="bottom" colspan="3" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p
style="margin:0in; text-align: center; "><b><font style="font-family:Arial;font-size:8pt;">Transgenomic, Inc.</font></b></p><p style="margin:0in; text-align: center; "><b><font style="font-family:Arial;font-size:8pt;">Summary Financial Results</font></b></p><p style="margin:0in; text-align: center; "><b><font style="font-family:Arial;font-size:8pt;">Modified EBITDA</font></b></p><p style="margin:0in; text-align: center; "><b><font style="font-family:Arial;font-size:8pt;">(dollars in thousands)</font></b></p><br /><p style=" margin:0in;"><font style="font-family:Arial;font-size:8pt;">Management uses Modified EBITDA, a non-GAAP measure, to measure the Company&#39;s financial performance and to internally manage its businesses. &#160;Management believes that Modified EBITDA provides useful information to investors as a measure of comparison with peer and other companies. &#160;Modified
EBITDA should not be considered an alternative to, or more meaningful than, net income or cash flow as determined in accordance with generally accepted accounting principles. &#160;Modified EBITDA calculations may vary from company to company. &#160;Accordingly, our computation of Modified EBITDA may not be comparable with a similarly-titled measure of another company.</font></p><br /><p style=" margin:0in;"><font style="font-family:Arial;font-size:8pt;">The following sets forth the reconciliation of Net Loss to Modified EBITDA for the periods indicated:</font></p><br /></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" colspan="2" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; text-align: center; "><b><font style="font-family:Arial;font-size:8pt;">Three Months Ended </font></b></p><p style="margin:0in;
text-align: center; "><b><font style="font-family:Arial;font-size:8pt;">March 31</font></b><b><font style="font-family:Arial;font-size:8pt;">,</font></b></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><u><b><font style="font-family:Arial;font-size:8pt;">2011</font></b></u></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><u><b><font style="font-family:Arial;font-size:8pt;">2010</font></b></u></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom"
style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style=" margin:0in;"><b><font style="font-family:Arial;font-size:8pt;">NET LOSS</font></b></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">$ &#160;(2,778)</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">$ &#160; &#160; &#160;(324)</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt
2pt 5.4pt;"><br /></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style=" margin:0in;"><b><font style="font-family:Arial;font-size:8pt;">INTEREST EXPENSE</font></b></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">238</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 10pt; "><p style="margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">&#8212;</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td style=""></td></tr><tr><td valign="bottom"
style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style=" margin:0in;"><b><font style="font-family:Arial;font-size:8pt;">INCOME TAXES BENEFIT</font></b></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">(6)</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">(51)</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="
margin:0in;"><b><font style="font-family:Arial;font-size:8pt;">DEPRECIATION AND AMORTIZATION</font></b></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">494</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">165</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style=" margin:0in;"><b><font
style="font-family:Arial;font-size:8pt;">PREFERRED STOCK &#160;EXPENSES</font></b></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">2,027</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 10pt; "><p style="margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">&#8212;</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style=" margin:0in;"><b><font style="font-family:Arial;font-size:8pt;">STOCK OPTION
EXPENSE</font></b></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><u><font style="font-family:Arial;font-size:8pt;">9</font></u></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 10pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><u><font style="font-family:Arial;font-size:8pt;">1</font></u></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style=" margin:0in;"><b><font style="font-family:Arial;font-size:8pt;">MODIFIED EBITDA</font></b></p></td><td
valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="border-bottom:double black 2.5pt;"><font style="font-family:Arial;font-size:8pt;">$ &#160;(16)</font></font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="border-bottom:double black 2.5pt;"><font style="font-family:Arial;font-size:8pt;">$ &#160;(209)</font></font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td style=""></td></tr><tr><td valign="bottom" colspan="3" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td
style=""></td></tr><tr><td style="padding: 0pt 5.4pt 2pt 5.4pt;"></td><td style="padding: 0pt 5.4pt 2pt 5.4pt;"></td><td style="padding: 0pt 5.4pt 2pt 5.4pt;"></td></tr></table><br /><br /></div><div style="margin-bottom:.0001in; margin-top:.0001in"><table cellspacing="0" cellpadding="1" style="border-collapse:collapse;border:none;"><tr><td valign="bottom" colspan="3" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; text-align: center; "><b><font style="font-family:Arial;font-size:8pt;">Transgenomic, Inc.</font></b></p><p style="margin:0in; text-align: center; "><b><font style="font-family:Arial;font-size:8pt;">Summary Financial Results</font></b></p><p style="margin:0in; text-align: center; "><b><font style="font-family:Arial;font-size:8pt;">Unaudited Condensed Consolidated Summary Balance Sheet Information</font></b></p><p style="margin:0in; text-align: center; "><b><font
style="font-family:Arial;font-size:8pt;">(dollars in thousands)</font></b></p><br /></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; text-align: center; "><b><font style="font-family:Arial;font-size:8pt;">March 31,</font></b></p><p style="white-space: nowrap;  margin:0in; text-align: center; "><u><b><font style="font-family:Arial;font-size:8pt;">2011</font></b></u></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; text-align: center; "><b><font style="font-family:Arial;font-size:8pt;">December 31,</font></b></p><p style="white-space: nowrap;  margin:0in; text-align: center; "><u><b><font style="font-family:Arial;font-size:8pt;">2010</font></b></u></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt
5.4pt 2pt 5.4pt;"><p style="margin:0in; text-align: center; "><b><font style="font-family:Arial;font-size:8pt;">ASSETS</font></b></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style=" margin:0in;"><font style="font-family:Arial;font-size:8pt;">CURRENT ASSETS:</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; margin-left: 12pt;"><font style="font-family:Arial;font-size:8pt;">Cash and cash equivalents</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p
style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">$ &#160;3,170</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">$ &#160;3,454</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; margin-left: 12pt;"><font style="font-family:Arial;font-size:8pt;">Accounts receivable</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">7,551</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in;
text-align: right; "><font style="font-family:Arial;font-size:8pt;">7,601</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; margin-left: 12pt;"><font style="font-family:Arial;font-size:8pt;">Inventories</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">3,163</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">3,344</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; margin-left: 12pt;"><font style="font-family:Arial;font-size:8pt;">Other current
assets</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><u><font style="font-family:Arial;font-size:8pt;">762</font></u></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><u><font style="font-family:Arial;font-size:8pt;">635</font></u></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; margin-left: 36pt;"><font style="font-family:Arial;font-size:8pt;">Total current assets</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">14,646</font></p></td><td valign="bottom"
style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">15,034</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style=" margin:0in;"><font style="font-family:Arial;font-size:8pt;">PROPERTY AND EQUIPMENT, NET</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">1,661</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">1,602</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt
5.4pt;"><p style=" margin:0in;"><font style="font-family:Arial;font-size:8pt;">OTHER ASSETS:</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; margin-left: 12pt;"><font style="font-family:Arial;font-size:8pt;">Goodwill</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">6,275</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">6,275</font></p></td><td style=""></td></tr><tr><td
valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; margin-left: 12pt;"><font style="font-family:Arial;font-size:8pt;">Intangibles</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">8,664</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">8,962</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; margin-left: 12pt;"><font style="font-family:Arial;font-size:8pt;">Other assets</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space:
nowrap;  margin:0in; text-align: right; "><u><font style="font-family:Arial;font-size:8pt;">152</font></u></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><u><font style="font-family:Arial;font-size:8pt;">154</font></u></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="border-bottom:double black 2.5pt;"><font style="font-family:Arial;font-size:8pt;">$31,398</font></font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="border-bottom:double black 2.5pt;"><font
style="font-family:Arial;font-size:8pt;">$32,027</font></font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; text-align: center; "><b><font style="font-family:Arial;font-size:8pt;">LIABILITIES AND STOCKHOLDERS&#39; EQUITY</font></b></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt
5.4pt;"><br /></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; margin-left: 36pt;"><font style="font-family:Arial;font-size:8pt;">Total current liabilities</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">8,340</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">8,253</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; margin-left: 12pt;"><font style="font-family:Arial;font-size:8pt;">Long term debt less current maturities</font></p></td><td
valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">8,640</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">8,640</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; margin-left: 12pt;"><font style="font-family:Arial;font-size:8pt;">Series A convertible preferred stock liabilities</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">7,914</font></p></td><td valign="bottom"
style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">5,791</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; margin-left: 12pt;"><font style="font-family:Arial;font-size:8pt;">Other long term liabilities</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><u><font style="font-family:Arial;font-size:8pt;">918</font></u></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><u><font style="font-family:Arial;font-size:8pt;">843</font></u></p></td><td style=""></td></tr><tr><td valign="bottom"
style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style="margin:0in; margin-left: 36pt;"><font style="font-family:Arial;font-size:8pt;">Total liabilities</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">25,812</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="font-family:Arial;font-size:8pt;">23,527</font></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><p style=" margin:0in;"><font style="font-family:Arial;font-size:8pt;">STOCKHOLDERS&#39; EQUITY</font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;
margin:0in; text-align: right; "><u><font style="font-family:Arial;font-size:8pt;">5,586</font></u></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><u><font style="font-family:Arial;font-size:8pt;">8,500</font></u></p></td><td style=""></td></tr><tr><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="border-bottom:double black 2.5pt;"><font style="font-family:Arial;font-size:8pt;">$ &#160;31,398</font></font></p></td><td valign="bottom" style="padding: 0pt 5.4pt 2pt 5.4pt;padding-right: 6pt; "><p style="white-space: nowrap;  margin:0in; text-align: right; "><font style="border-bottom:double black 2.5pt;"><font
style="font-family:Arial;font-size:8pt;">$ &#160;32,027</font></font></p></td><td style=""></td></tr><tr><td valign="bottom" colspan="3" style="padding: 0pt 5.4pt 2pt 5.4pt;"><br /></td><td style=""></td></tr><tr><td style="padding: 0pt 5.4pt 2pt 5.4pt;"></td><td style="padding: 0pt 5.4pt 2pt 5.4pt;"></td><td style="padding: 0pt 5.4pt 2pt 5.4pt;"></td></tr></table><br /><br /></div><p></p><br /><br /><p>CONTACT:  Investor Relations of Transgenomic, Inc., +1-402-452-5400, investorrelations@transgenomic.com</p></div></div></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
